- Claritas Pharmaceuticals (CLAS) has obtained approval from the OTC Markets Group to list its common shares on the OTCQB under the ticker symbol CLAZF
- The company will continue to trade on the TSXV under the symbol CLAS
- The OTCQB uplisting will make the company accessible to a much broader range of U.S. investors and brokers
- Claritas Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
- Claritas Pharmaceuticals, Inc. (CLAS) opened trading at $0.17 per share
Claritas Pharmaceuticals (CLAS) has obtained approval to list its common shares on the OTCQB under the ticker symbol CLAZF.
Robert Farrell, the company’s President and CEO commented on the news.
“We are very pleased to report that we have met all requirements and have been accepted by OTC Markets to up-list to the OTCQB tier for trading. We undertook the stringent qualification process for the OTCQB listing because we believe that trading on the OTCQB tier will bring added value to our shareholders. The OTCQB listing will elevate our profile within the investment community and is consistent with our long-term strategy to introduce the Company to a broader investor audience in the U.S. This upgrade is a significant milestone and a step toward the NASDAQ listing that we anticipate will occur next year.”
Claritas Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for patients with significant unmet medical needs.
Claritas Pharmaceuticals, Inc. (CLAS) opened trading at $0.17 per share.
